抗表皮生长因子受体抗体-药物偶联物MRG003治疗晚期实体瘤的安全性评价

IF 22.5 1区医学 Q1 ONCOLOGY

JAMA Oncology Pub Date : 2022-05-05 DOI:10.1001/jamaoncol.2022.0503

M. Qiu, Yang Zhang, Ye Guo, W. Guo, Weiqi Nian, W. Liao, Zhongyuan Xu, Wenxue Zhang, Hongzhe Zhao, Xiaoli Wei, L. Xue, W. Tang, Yunteng Wu, G. Ren, Ling Wang, Jingle Xi, Yongshuai Jin, Hu Li, Chaohong Hu, R. Xu

{"title":"抗表皮生长因子受体抗体-药物偶联物MRG003治疗晚期实体瘤的安全性评价","authors":"M. Qiu, Yang Zhang, Ye Guo, W. Guo, Weiqi Nian, W. Liao, Zhongyuan Xu, Wenxue Zhang, Hongzhe Zhao, Xiaoli Wei, L. Xue, W. Tang, Yunteng Wu, G. Ren, Ling Wang, Jingle Xi, Yongshuai Jin, Hu Li, Chaohong Hu, R. Xu","doi":"10.1001/jamaoncol.2022.0503","DOIUrl":null,"url":null,"abstract":"Key Points Question What is the safety and antitumor activity of MRG003 in patients with advanced solid tumors? Findings In this phase 1 clinical trial of 61 patients with advanced or metastatic solid tumors, treatment with MRG003 exhibited manageable safety and showed encouraging antitumor activity in squamous cell carcinomas of the head and neck and nasopharyngeal carcinoma, with a confirmed objective response rates of 40% and 44%, respectively. Meaning The study findings suggest the safety of treatment with MRG003 and an acceptable tolerance in most patients with epidermal growth factor receptor–expressing solid tumors, as well as encouraging antitumor activity in patients with squamous cell carcinomas of the head and neck and nasopharyngeal carcinoma.","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"8 1","pages":"1042 - 1046"},"PeriodicalIF":22.5000,"publicationDate":"2022-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":"{\"title\":\"Evaluation of Safety of Treatment With Anti–Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors\",\"authors\":\"M. Qiu, Yang Zhang, Ye Guo, W. Guo, Weiqi Nian, W. Liao, Zhongyuan Xu, Wenxue Zhang, Hongzhe Zhao, Xiaoli Wei, L. Xue, W. Tang, Yunteng Wu, G. Ren, Ling Wang, Jingle Xi, Yongshuai Jin, Hu Li, Chaohong Hu, R. Xu\",\"doi\":\"10.1001/jamaoncol.2022.0503\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Key Points Question What is the safety and antitumor activity of MRG003 in patients with advanced solid tumors? Findings In this phase 1 clinical trial of 61 patients with advanced or metastatic solid tumors, treatment with MRG003 exhibited manageable safety and showed encouraging antitumor activity in squamous cell carcinomas of the head and neck and nasopharyngeal carcinoma, with a confirmed objective response rates of 40% and 44%, respectively. Meaning The study findings suggest the safety of treatment with MRG003 and an acceptable tolerance in most patients with epidermal growth factor receptor–expressing solid tumors, as well as encouraging antitumor activity in patients with squamous cell carcinomas of the head and neck and nasopharyngeal carcinoma.\",\"PeriodicalId\":14850,\"journal\":{\"name\":\"JAMA Oncology\",\"volume\":\"8 1\",\"pages\":\"1042 - 1046\"},\"PeriodicalIF\":22.5000,\"publicationDate\":\"2022-05-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAMA Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1001/jamaoncol.2022.0503\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamaoncol.2022.0503","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 9

摘要

要点问题MRG003在晚期实体瘤患者中的安全性和抗肿瘤活性是什么？研究结果在这项针对61名晚期或转移性实体瘤患者的1期临床试验中，MRG003治疗显示出可控的安全性，并在头颈部鳞状细胞癌和鼻咽癌中显示出令人鼓舞的抗肿瘤活性，经证实的客观有效率分别为40%和44%。研究结果表明，MRG003治疗的安全性和对大多数表皮生长因子受体表达实体瘤患者的可接受耐受性，以及对头颈部鳞状细胞癌和鼻咽癌患者的抗肿瘤活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Evaluation of Safety of Treatment With Anti–Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors

Key Points Question What is the safety and antitumor activity of MRG003 in patients with advanced solid tumors? Findings In this phase 1 clinical trial of 61 patients with advanced or metastatic solid tumors, treatment with MRG003 exhibited manageable safety and showed encouraging antitumor activity in squamous cell carcinomas of the head and neck and nasopharyngeal carcinoma, with a confirmed objective response rates of 40% and 44%, respectively. Meaning The study findings suggest the safety of treatment with MRG003 and an acceptable tolerance in most patients with epidermal growth factor receptor–expressing solid tumors, as well as encouraging antitumor activity in patients with squamous cell carcinomas of the head and neck and nasopharyngeal carcinoma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

JAMA Oncology Medicine-Oncology

自引率

1.80%

发文量

423

期刊介绍： JAMA Oncology is an international peer-reviewed journal that serves as the leading publication for scientists, clinicians, and trainees working in the field of oncology. It is part of the JAMA Network, a collection of peer-reviewed medical and specialty publications.